China Heparin Industry Report, 2012-2014

465 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
465
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

China Heparin Industry Report, 2012-2014

  1. 1. China Heparin Industry Report, 2012-2014Report Details:Published:December 2012No. of Pages: 73Price: Single User License – US$1900China, abundant in heparin raw materials, has become one of the world’s largest heparin APIproducers and exporters, owning to the quality of heparin API having won international recognitiongradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled thatthe heparin export standard has lifted, China’s export volume of heparin API was no more than105.2 tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportionof around 45.9% in the global demand during the same period.Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, ChangzhouQianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend BiochemicalPharmaceutical, which have ranked top 4 industrial players by export for several years in a row,with the combined export value making up more than 70% of China’s total export value of heparin.There is no distinct change in terms of the export pattern. However, the export prices of China’stop 10 heparin exporters witnessed a downward mobility in 2011-2012H1. Nevertheless, it was notthe same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care ArticleImp. & Exp. (Group), whose export prices increased by 3.8% and 2.1% year-on-year respectivelyin Jan.-May, 2012, due to the improved quality of exported products as well as the low cardinalnumber of exported prices in the preceding year.Meanwhile, Chinese heparin API flagship enterprises including Shenzhen HepalinkPharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals, HebeiChangshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical areprojected to expand their capacities and improve the heparin industry chains. Among thesetycoons, the first four ones have made IPO, while Nanjing King-Friend BiochemicalPharmaceutical is also preparing for IPO by accepting tutoring. According to public informationissued by related enterprises, the heparin API capacity of China will increase by more than 18trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over70% of the global demand.Although China is a large country with rich heparin API, the downstream production of generalheparin preparation and low molecular weight heparin preparation is still at the initial stage. In thehigh-end low molecular weight heparin preparation market, especially, joint ventures and foreignbrands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. Accordingto China Pharmaceutical Industry Association, imported low molecular weight heparin calciumaccounted for more than 60% of the total procurement of such products of representative hospitals
  2. 2. in 22 Chinese cities in 2011.However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing. A case inpoint is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecularweight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, withthe sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales ofRMB117 million in 2012H1, a year-on-year rise of 237.6%.Get your copy of this report @http://www.reportsnreports.com/reports/209114-china-heparin-industry-report-2012-2014.htmlMajor points covered in Table of Contents of this report includeTable of Contents1. Profile of Heparin Industry1.1 Definition & Classification1.2 Industry Chain2. Operating Environment of Chinese Heparin Industry2.1 Entry Barriers2.1.1 Policies2.1.2 Technical Requirements2.1.3 Capital Barrier2.2 Supply and Demand in Global Market2.3 Competition in Global Market2.4 Global Market Forecast3. Development of Heparin API Industry in China3.1 Market Status Quo3.2 Market Supply and Demand3.3 Competitive Landscape3.4 Import & Export3.4.1 Export3.4.2 Import3.5 Development Outlook & Forecast4. Development of Heparin Preparation Industry in China4.1 Market Size4.2 Competition Pattern4.3 Market Segments4.3.1 Low Molecular Weight Heparin Preparation4.3.2 General Heparin Preparation4.4 Development Outlook & Forecast5. Key Chinese Heparin Manufacturers5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd5.1.1 Profile
  3. 3. 5.1.2 Operation5.1.3 Revenue Structure5.1.4 Gross Margin5.1.5 R&D and Investment5.1.6 Clients and Suppliers5.1.7 Prospects5.2 Changzhou Qianhong Bio-Pharma Co., Ltd5.2.1 Profile5.2.2 Operation5.2.3 Revenue Structure5.2.4 Gross Margin5.2.5 R&D and Investment5.2.6 Clients and Suppliers5.2.7 Heparin Business5.2.8 Prospects5.3 Yantai Dongcheng Biochemicals Co., Ltd5.3.1 Profile5.3.2 Operation5.3.3 Revenue Structure5.3.4 Gross Margin5.3.5 R&D and Investment5.3.6 Clients and Suppliers5.3.7 Heparin Business5.3.8 Prospects5.4 Hebei Changshan Biochemical Pharmaceutical Co., Ltd5.4.1 Profile5.4.2 Operation5.4.3 Revenue Structure5.4.4 Gross Margin5.4.5 R&D and Investment5.4.6 Clients and Suppliers5.4.7 Prospects5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd5.5.1 Profile5.5.2 Operation5.5.3 Revenue Structure5.5.4 Gross Margin5.5.5 R&D and Investment5.5.6 Clients and Suppliers5.5.7 Heparin Business5.5.8 Prospects5.6 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
  4. 4. 5.6.1 Profile5.6.2 Operation and Prospects5.7 Wanbang Biopharmaceuticals5.7.1 Profile5.7.2 Operation and ProspectsList of ChartsApplication of Heparin PreparationsHeparin Industry ChainDifference between Heparin Sodium API and Heparin Standardized RequirementsHeparin Preparation Market Scale and YoY Growth Worldwide, 2006-2011Performance: Low Molecular Weight Heparin Preparation vs. General Heparin PreparationGlobal Heparin Preparation Distribution by Region, 2011Heparin API Demand and YoY Growth Worldwide, 2007-2011Sales of Enoxaparin Worldwide by Product, 2010-2012Regulatory Exclusivity of Lovenox, as of late 2011Global Heparin Preparation Market Scale, 2011-2014EGlobal Heparin API Demand, 2011-2014EGross Margin of Major Heparin API Manufacturers in China, 2008-2012Capacity of Crude Heparin in China, 2009-2011Average Export Price of Heparin and Heparinate, 2008-2012Capacity of Major Heparin API Manufacturers in China, as of June 2012Export Volume and Export Value of Heparin and Heparinate in China, 2008-2012Export Price of Heparin and Heparinate in China, 2008-2012Top 10 Export Destinations of Heparin and Heparinate in China by Value, 2011-2012Top 10 Heparin and Heparinate Enterprises in China by Export Value, 2011Export Volume and Export Value of Heparin and Heparinate in China, Jan.-May, 2012Import Volume, Import Value and Unite Price of Heparin and Heparinate in China, 2008-2011Planned / Ongoing Heparin Sodium API Projects in China, as of June 2012Heparin Preparation Market Scale and YoY Growth of China, 2007-2011Market Share of Heparin Preparation Products in China, 2011Main Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solutionin ChinaManufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular HeparinCalcium PreparationsChina Low Molecular Weight Heparin Preparation Market Scale, 2009-2011Purchase Value of Low Molecular Weight Heparin Calcium of Chinese Representative Hospitals,2010-2011Low Molecular Weight Heparin Preparation Imported Value of Representative Hospitals in 22Chinese Cities, 2010-2011Competition Pattern of China Low Molecular Weight Heparin Calcium Market, 2009Competition Pattern of China Low Molecular Weight Heparin Sodium Market, 2009China Heparin Preparation Market Scale and YoY Growth, 2011-2014
  5. 5. Assets and Net Income of Holding Subsidiaries under Hepalink, 2012H1Revenue and Profit of Hepalink, 2008-2012Revenue of Hepalink by Product, 2008-2012Revenue of Hepalink by Region, 2008-2012Gross Margin of Hepalink by Product, 2008-2012R&D Investment and Proportion in Revenue of Hepalink, 2009-2011Revenue of Hepalink from the Top 5 Clients and Proportion, 2008-2012Revenue and Operating Income of Hepalink, 2011-2014EAssets, Revenue and Net Income of Subsidiaries under Qianhong Bio-Pharma, 2012H1Revenue and Profit of Qianhong Bio-Pharma, 2008-2012Revenue of Qianhong Bio-Pharma by Product, 2008-2012Revenue of Qianhong Bio-Pharma by Region, 2008-2012Gross Margin of Qianhong Bio-Pharma by Product, 2008-2012R&D Investment and Proportion in Revenue of Qianhong Bio-Pharma, 2009-2011Scheduling of Planned/Ongoing Projects of Qianhong Bio-Pharma, as of June 2012Top 5 Clients, Revenue Contribution and Proportion of Qianhong Bio-Pharma, 2011Purchase Value of Qianhong Bio-Pharma’s Top 5 Suppliers and Revenue Contribution ofQianhong Bio-Pharma’s Top 5 Clients, 2009-2012Revenue and Gross Margin from Heparin Business of Qianhong Bio-Pharma, 2008-2012Revenue and Operating Income of Qianhong Bio-Pharma, 2011-2014Assets, Revenue and Net Income of Subsidiaries under Dongcheng Biochemicals, 2012H1Revenue and Profit of Dongcheng Biochemicals, 2008-2012Revenue of Dongcheng Biochemicals by Product, 2008-2012Revenue of Dongcheng Biochemicals by Region, 2008-2012Gross Margin of Dongcheng Biochemicals by Product, 2008-2012R&D Investment and Proportion in Revenue of Dongcheng Biochemicals, 2008-2012Revenue and Gross Margin from Heparin Sodium API Business of Dongcheng Biochemicals,2008-2012Heparin Sodium API Price of Dongcheng Biochemicals, 2009-2011Revenue Contribution of Dongcheng Biochemicals’ Top 5 Heparin Sodium API Clients, 2009-2011Scheduling of Heparin Sodium API Projects of Dongcheng Biochemicals, 2013-2015ERevenue and Profit of Dongcheng Biochemicals, 2011-2014ERevenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2008-2012Revenue of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012Revenue of Hebei Changshan Biochemical Pharmaceutical by Region, 2008-2012Gross Margin of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012R&D Investment and Proportion in Revenue of Hebei Changshan Biochemical Pharmaceutical,2009-2011Product Research Scheduling of Hebei Changshan Biochemical Pharmaceutical, as of late 2011Name List, Revenue Contribution and Proportion of Top 5 Clients of Hebei ChangshanBiochemical Pharmaceutical, 2011Heparin Product Certificates Won by Hebei Changshan Biochemical Pharmaceutical Overseas, as
  6. 6. of late 2011Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2011-2014ERevenue and Profit of Tianjin Chase Sun Pharmaceutical, 2008-2012Revenue of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012Revenue of Tianjin Chase Sun Pharmaceutical by Region, 2008-2012Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012R&D Investment and Proportion in Revenue of Tianjin Chase Sun Pharmaceutical, 2009-2011Name List, Revenue Contribution and Proportion of Top 5 Clients of Tianjin Chase SunPharmaceutical, 2011Name List, Purchase Value and Proportion of Top 5 Suppliers of Tianjin Chase SunPharmaceutical, 2011Revenue and Gross Margin from Heparin Business of Tianjin Chase Sun Pharmaceutical, 2008-2012Revenue and Operating Income of Tianjin Chase Sun Pharmaceutical, 2011-2014Assets and Net Income of Wanbang Biopharmaceuticals, 2008-2011Contact: sales@reportsandreports.com for more information.

×